Literature DB >> 19675911

A temporary stereocentre approach for the asymmetric synthesis of chiral cyclopropane-carboxaldehydes.

Matt Cheeseman1, Iwan R Davies, Phil Axe, Andrew L Johnson, Steven D Bull.   

Abstract

A novel way of combining chiral auxiliaries and substrate directable reactions is described that employs a three-step sequence of aldol/cyclopropanation/retro-aldol reactions for the asymmetric synthesis of enantiopure cyclopropane-carboxaldehydes. In the first step, reaction of the boron enolate of (S)-N-propionyl-5,5-dimethyl-oxazolidin-2-one with a series of alpha,beta-unsaturated aldehydes affords their corresponding syn-aldol products in high de. In the second step, directed cyclopropanation of the alkene functionalities of these syn-aldols occurs under the stereodirecting effect of their 'temporary'beta-hydroxyl stereocentres to give a series of cyclopropyl-aldols in high de. Finally, retro-aldol cleavage of the lithium alkoxide of these cyclopropyl-aldols results in destruction of their temporary beta-hydroxy stereocentres to afford the parent chiral auxiliary and chiral cyclopropane-carboxaldehydes in >95% ee. The potential of this methodology has been demonstrated for the asymmetric synthesis of the cyclopropane containing natural product cascarillic acid in good yield.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675911     DOI: 10.1039/b908600e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  2 in total

1.  Synthesis of (2S)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic Fluorination.

Authors:  Coralie De Schutter; Ozkan Sari; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  J Org Chem       Date:  2017-12-04       Impact factor: 4.354

2.  Solid-phase asymmetric synthesis using a polymer-supported chiral Evans'-type oxazolidin-2-one.

Authors:  Rachel Green; Jennifer Peed; James E Taylor; Richard A R Blackburn; Steven D Bull
Journal:  Nat Protoc       Date:  2013-09-12       Impact factor: 13.491

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.